At Biogen Idec, we have a passionate commitment to discover, develop and deliver innovative therapies that improve the lives of patients, with a specific focus on neurology, hematology and immunology.
Our expertise and commitment have produced the industry’s most robust MS franchise, helping to manage the disease from its earliest signs through its later stages. Our vision is to extend this leadership to transform the standard of care for hemophilia, to excel in discovery science and continue innovating at the intersection of science, medicine and economics to transform drug development.
Our commitment to improving patients’ lives goes beyond the treatments we develop; we also work to support patients and their caregivers with a range of best-in-class services. For example, we’ve created a number of programs under the MS ActiveSource® umbrella to help with the informational, emotional and logistical considerations that are part of living with MS.
We also help patients and their families address the financial impact of treatment through our ActiveAccess™ program. In 2013, Biogen Idec provided nearly $710 million in financial assistance in the form of free drug, drug copay assistance, infusion assistance and charitable contributions.
Biogen Idec’s access and assistance programs have set a standard in MS. We are bringing the same commitment to the hemophilia community through our programs, MyALPROLIX™ and MyELOCTATE™. Our aim is to provide comprehensive assistance programs to find the most cost effective means for the community to access ALPROLIX and ELOCTATE. We are offering a variety of assistance programs based on the needs of people with hemophilia and shaped by community input, including a copay program, financial counseling and a free trial program.